-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

Benzinga·09/11/2026 10:04:47
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.